Northwest Biotherapeutics, Inc. (NWBO) ended last trading session with a change of -6.58 percent. It trades at an average volume of 1.73M shares versus 1.9M shares recorded at the end of last trading session. The share price of $0.35 is at a distance of 10.94 percent from its 52-week low and down -80.71 percent versus its peak. The company has a market cap of $54.46M and currently has 153.41M shares outstanding. The share price is currently -11.05 percent versus its SMA20, -11.45 percent versus its SMA50, and -26.41 percent versus its SMA200. The stock has a weekly performance of -3.79 percent and is 1.99 percent year-to-date as of the recent close.
March 10, 2017 — Northwest Biotherapeutics, Inc. (NWBO) a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors (“Whitebox”), holder of $11 million of NW Bio convertible senior notes.
With these Notes otherwise due, as previously disclosed, NW Bio and Whitebox have negotiated a time payment approach tailored to the Company’s development schedule with increasing periodic payments over the course of the next 4 months. As part of the consideration for these adjustments, Whitebox also will be receiving NW Bio common stock.
Cempra, Inc. (CEMP) recently recorded 4.17 percent change and currently at $3.75 is 47.06 percent away from its 52-week low and down -86.09 percent versus its peak. It has a past 5-day performance of 4.17 percent and trades at an average volume of 2.78M shares. The stock has a 1-month performance of 22.95 percent and is 33.93 percent year-to-date as of the recent close. There were about 52.39M shares outstanding which made its market cap $196.46M. The share price is currently 8.07 percent versus its SMA20, 12.31 percent versus its SMA50, and -73 percent versus its SMA200.
On March 13, 2017 Cempra, Inc. (CEMP) announced that the company has retained Morgan Stanley & Co. LLC as financial advisor to the company and to lead its recently announced process to review strategic business options.
The goal of this process is for Cempra to determine the best use of its significant cash resources and clinical programs to deliver value to patients and shareholders through internal and/or potential external opportunities. As of December 31, 2016, Cempra had cash and equivalents of $231.6 million.